Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYN023 for treatment of rabies in adults
ChiCTR2600119558Phase 4Recruiting
- Sponsor
- Peking University First Hospital
- Start
- Feb 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of zamerovimab + mazorelvimab in rabies, sponsored by Peking University First Hospital. Primary endpoints: Safety endpoint: adverse reactions and serious adverse events within 5 days after SYN023 administration and Efficacy endpoint: survival rate on Day 5 after SYN023 administration. Started Feb 2026; status: recruiting.
02
Drugs
zamerovimab + mazorelvimab
03
Conditions
rabies
Beyond the preview
Go deeper on ChiCTR2600119558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600119558.